Cytonus introduces a cell-based drug delivery platformPublished: February 6, 2019
San Diego-based Cytonus Therapeutics has developed a cell-based platform, Cargocytes™, for the precise delivery of biologics to targeted tissues.
Cargocytes are engineered allogenic cell lines designed to carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
Results from preclinical studies have shown the potential of cargocytes in improving the efficiency of payload delivery, reducing adverse reactions, reducing the required dosing regimen and mediating anti-cancer immunity against solid tumors and metastases.
Cytonus’ focus is to advance Cargocyte™ candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases, the initial focus being pancreatic adenocarcinoma. GM1215 is a cargocyte specially developed to target pancreas and is loaded with cytokine immune stimulators to treat pancreas adenocarcinoma.
Cytonus Therapeutics is a spinout biotechnology company based on work done by founder and CSO Dr Richard Klemke, professor of pathology at University of California San Diego School of Medicine.
Dr Remo Moomiaie-Qajar, president and CEO of Cytonus commented: “Our technology revolutionizes the ability of cells to transport vital therapeutic payloads to targeted tissues in a safe, controllable, predictable and precise manner. We believe our Cargocytes have many structural and functional attributes making them the most versatile and capable cell-based drug delivery platform. Our different approach is well suited to address some of the most difficult to treat cancers and expands the possibilities of using various payloads to influence the immune system for many medical applications.”
Source: New Cell-Based Technology by Cytonus Aims to Revolutionize the Fight against Cancer and Inflammatory Diseases; Press Release